Galapagos N.V. EBIT

The latest EBIT for GLPG.BR is $590M as of June 2026. That compares with $-380M in the prior-year period — up 256.6% year over year. That is below the Healthcare sector average of $99B. Investors often review this figure alongside Galapagos N.V.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, GLPG.BR's EBIT moved from $-380M to $590M — a 256.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Galapagos N.V.'s operating scale or balance-sheet position.

Against Healthcare companies, GLPG.BR currently prints $590M for EBIT, while the sector average sits near $99B. That is roughly 99.4% below the sector mean. Large gaps often invite a closer look at Galapagos N.V.'s growth, margins, and balance sheet.

A EBIT figure of $590M for GLPG.BR is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $99B. Explore the charts below for those layers of context.

After noting GLPG.BR's EBIT ($590M), review year-over-year change from $-380M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.